Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or...
Reexamination Certificate
1999-11-19
2002-06-25
Navarro, Mark (Department: 1645)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
C435S237000, C435S239000, C424S093100, C424S093210, C424S229100, C514S04400A, C536S023100, C536S023720, C536S027400
Reexamination Certificate
active
06410297
ABSTRACT:
INTRODUCTION
The present invention relates to the use of continuous avian cell lines that support the growth and productive infection of Marek's Disease Virus (MDV) at high titers. The present invention relates to a cell line that can be used as a substrate to efficiently propagate large quantities of Marek's disease virus, in particular, for vaccine production. The present invention relates to recombinant Marek's disease viral vectors and cell lines to package said vectors and recombinant Marek's disease viruses which may be used as vaccines. Marek's Disease Virus vectors and vaccines may be used to protect avians from infection with Marek's Disease Virus and against disease resulting from infection.
BACKGROUND OF THE INVENTION
Marek's Disease (MD) is an acutely oncogenic disease of chickens, which causes lymphomas, visceral tumors, nerve lesions and immunosuppression. The disease is global and ubiquitous in distribution. The etiologic agent is a herpesvirus, Marek's Disease Virus. Marek's Disease has been a primary cause of deaths and condemnations in broiler flocks [Calnek, B. W. and Witter, R. L., Diseases of Poultry, 9th edition, Iowa State Press, Ames, Iowa, pp. 342-385(1991)].
There are three serotype of Marek's Disease Virus. Serotype 1 includes all pathogenic strains and their attenuated derivatives. Serotype 2 consists of naturally avirulent chicken viruses, while serotype 3, also known as Herpesvirus of Turkeys (HVT), includes avirulent turkey viruses that are capable of replication in chickens. The three serotypes are partially cross-protective, but can be distinguished using polyclonal or monoclonal antibody tests, polypeptide patterns and DNA analysis (Silva, R. F. and Lee, L. F., Virol. vol. 36, pp. 307-25 320 (1984); Payne, L. N., in “Encyclopedia of Virology” Edited by Webster, R. G. & Granoff, A., pp. 832-838 (1994)) and other known methods.
The DNA genome of MDV serotype 1 and HVT are linear double-stranded molecules of approximately 180 and 167 kilobases, respectively. Similar to other herpes viruses, the genome of MDV consists of a long unique region (UL) and a short unique region (US) surrounded by inverted repeats. The genomes of the three MDV serotypes are in the form of full length closed circular DNA, however there is little homology between the three serotypes of MDV under stringent hybridization conditions even though their genomes are colinear [see Payne, L. N., in “Encyclopedia of Virology” edited by Webster R. G. and Granoff A., pp. 832-838 (1994)].
Marek's Disease Virus appears to be less recombinogenic than other herpesviruses, and the cell-associated nature of the virus makes plaque purification of recombinants away from parental virus problematic. Nevertheless, recombinant MD viruses have been generated from serotype 1 [Sonoda, K. et al., Vaccine V. 14, pp. 277-284 (1996); Parcells, M. S., et al., J. Virol., V. 69, pp. 7888-7898 (1995); Parcells M. S., et al., Virus Genes, V. 9, pp. 5-13, (1994Parcells, M. S., et al., J. Virol., V. 68, pp. 8239-8253 (1994); Sakaguchi, M., Vaccine V. 12, pp. 953-957 (1994); Reddy, S. K., et al., Vaccine V. 14, pp. 469-477 (1996)], serotype 2 [Marsha D. R., et al., Virol. V. 195, pp. 638-648 (1993); Silva, R. F., 14th International Herpesvirus Workshop (Abstract) (1989)]; and serotype 3 [Reddy, S. K., et al., Vaccine V. 14, pp. 469-477 (1996); PCT Parent Application WO 95/29248 (1995); Silva, R. F., 14th International Herpesvirus Workshop (Abstract) (1989); Darteil, R., et al., Virol. V. 211, pp. 481-490 (1995); U.S. Pat. No. 5,187,087 issued in 1995; Zelnik, V., et al., J. Gen. Virol. V. 76, pp. 2903-2907 (1995); PCT Patent Application WO 93/25665, published (1993); Ross, L. J. N., et al., J. Gen. Virol., V. 74, pp. 371-377 (1993), Sondermeijer, P.J.A., et al., Vaccine V. 11, pp. 349-358 (1993); European Patent No. 431,668 B1, published (1995); Morgan, R. W., et al., Avian Dis., V. 36, pp. 858-870 (1992); Bandyopadhyay, P. K., et al., 13th International Herpesvirus Workshop 323 (Abstract) (1988)]. In all of the above mentioned references, the viruses were replication competent and were produced in primary avian cells.
Commercially available Marek's Disease Virus vaccines, with the exception of some monovalent HVT formulations, consist largely of live Marek's Disease Virus-infected primary chicken embryo fibroblast (CEF) cells. A significant problem associated with using whole live Marek's Disease Virus-infected primary chicken cells to grow Marek's Disease Virus for use in vaccines is that the CEF cells must be stored at liquid nitrogen temperatures and administered by injection in order to be effective. Whole live cell vaccines have been previously necessary since the three Marek's Disease Virus serotypes are strongly cell-associated in cell culture and in most tissues of an infected bird. Spread of infection within birds can be achieved by direct cell to cell contact, with little or no cell-free virus being released. Infectious virions are produced only in the feather follicle epithelium (FFE), and are responsible for bird-to-bird transmission [Calnek, B. W., et al., Avian Dis., V. 14, pp. 219-233 (1970); Witter, R. L., et al., J. Natl. Cancer Inst., V. 49, pp. 1121-1130 (1972); Edison, C. S., et al., J. Natl. Cancer Inst., V. 47, pp. 113-120 (1971)].
Commercial cell-free Marek's Disease Virus vaccines can be made by cell culture. However, the production of cell-free Marek's Disease Virus vaccines has been thus far been limited to vaccines produced using only serotype 3 Marek's Disease Virus. This is because only serotype 3 Marek's Disease Virus makes free virions in sufficient quantities for production of Marek's Disease Virus vaccines. It has been suggested that lack of expression of the viral glycoprotein D (gD) gene may be involved in limiting release of cell-free virions [PCT Patent Application WO 95/29248 published (1995); Tan, X. and Velicer, L. F., 18th International Herpesvirus Workshop A, 145 (Abstract) (1993)].
In addition to CEF, other primary avian cells have been used to grow Marek's Disease Virus, including chicken embryo kidney (CEK) and duck embryo fibroblast (DEF). A chemically transformed quail cell line designated QT35 has been described as a substrate for avirulent serotypes 2 and 3 of Marek's Disease Virus, but not serotype 1. [Nikura, M., Nanta, T. et al., J. Vet. Med. Sci., V. 53, pp. 439446 (1991)]. A chemically transformed CEF cell line designated CHCC-OU2 [Ogura, H. and Fujiwara, T., Acta Med. Okayama, V. 41, pp. 141-143 (1987)] has been described as supporting the growth of Marek's Disease Virus-1 [Abujoub, A.
3
and Coussens, P. M., Virol., V. 214, pp. 541-549 (1985)].
Other known processes for producing Marek's Disease Virus include the use of tumorigenic or oncogenic cell lines. Marek's Disease Virus-transformed lymphoblastoid cell lines [Nazerian, K. Avian Pathol. V. 16, pp. 527-544 (1987)] are derived from lymphoid tumors in chickens infected with oncogenic Marek's Disease Virus-1. The viral genome is maintained in a latent or semi-latent state in these cells, such that transmission of infection to co-cultivated CEF cells or DEF cells occurs at a low frequency, if at all. In addition, these lymphoblastoid lines are refractory to superinfection with other Marek's Disease Virus viruses. Furthermore, Marek's Disease Virus-transformed lymphoblastoid cell lines have not demonstrated utility in the production of nonrecombinant (conventional) Marek's Disease Virus vaccines or in the preparation of recombinant Marek's Disease Virus viruses or genetically altered Marek's Disease Virus viruses or vectors.
Similarly, lymphoblastoid cell lines [Nazerian, K., Avian Pathol., V. 16, pp. 527-544 (1987)] derived from oncogenic avian retroviruses (avian leukosis virus and reticuloendotheliosis virus) are not useful fo
Rong Sing
Sheppard Michael G.
Baskar Padma
Ginsburg Paul H.
Myers Jeffrey N.
Navarro Mark
Pfizer Inc
LandOfFree
Processes for preparation of Marek's disease virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Processes for preparation of Marek's disease virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Processes for preparation of Marek's disease virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2953905